within Pharmacolibrary.Drugs.ATC.N;

model N06AA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AA08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dibenzepin is a tricyclic antidepressant (TCA) primarily used in the treatment of depression. It has similar pharmacological properties to other TCAs, acting as a potent inhibitor of norepinephrine and, to a lesser extent, serotonin reuptake. Dibenzepin has been used mainly in Europe and is not widely approved for use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are not reported in primary literature sources or public pharmacokinetic databases for healthy adults. The following values are estimates based on typical properties of tricyclic antidepressants.</p><h4>References</h4><ol><li><p>Gauch, R, &amp; Modestin, J (1973). [Pharmacokinetics of dibenzepin]. <i>Arzneimittel-Forschung</i> 23(5) 687–689. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4740212/&quot;>https://pubmed.ncbi.nlm.nih.gov/4740212</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AA08;
